Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Artiva Biotherapeutics, Inc. Common Stock

ARTV

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Last trade $3.82
Day change -$0.145 (-3.66%)
Day range $3.82 – $4.00
Volume 905,803
Market cap $196M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$195.75M
Price / earnings
—
Price / book
0.61×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.31×

Profitability

Earnings per share
-$1.98
Return on assets
-28.61%
Return on equity
-30.59%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
19.88×
Quick ratio
19.88×
Cash ratio
3.73×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$86.6M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ARTV, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$5.96M$4.97M$5.12M$4.94M$5.26M$4.95M$5.12M$4.95M
Research and development$25.99M$21.93M$19.31M$16.99M$17.63M$17.86M$17.05M$13.32M
Total operating expenses$31.95M$26.89M$24.43M$21.93M$22.9M$22.81M$22.17M$18.27M
Operating income-$31.95M-$26.89M-$24.43M-$21.93M-$22.9M-$22.81M-$22.17M-$18.27M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$28.82M-$25.01M-$23.52M-$20.77M-$21.53M-$21.25M-$20.31M-$16.1M
Income taxes$0$0$0$0$0$0$0$0
Net income-$28.82M-$25.01M-$23.52M-$20.77M-$21.53M-$21.25M-$20.31M-$16.1M
Net income attributable to common shareholders-$28.82M-$25.01M-$23.52M-$20.77M-$21.53M-$21.25M-$20.31M-$16.1M
EBITDA-$31.2M-$26.2M-$23.76M-$21.27M-$22.24M-$22.17M-$21.54M-$17.65M
Basic earnings per share-$0.56-$0.63-$0.95-$0.85-$0.88-$0.87-$0.83-$0.66
Diluted earnings per share-$0.56-$0.63-$0.95-$0.85-$0.88-$0.87-$0.83-$0.66

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

Artiva Biotherapeutics announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Miralles brings over 20 years of biotech leadership experience and previously served on Artiva's Board. The appointment comes as Artiva prepares for Phase 3 registrational trials of its lead program AlloNK in refractory rheumatoid arthritis, with plans to file a BLA in 2029.

GlobeNewswire Inc.

Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's 2026 report reveals a robust rheumatoid arthritis pipeline with 75+ active players developing 80+ drugs across various clinical stages. The report highlights emerging therapies targeting novel pathways beyond traditional TNF inhibition, including JAK inhibitors, BTK inhibitors, and cell-based immunotherapies. Recent developments include positive Phase III results for Lynk Pharmaceuticals' zemprocitinib, FDA Fast Track designation for Artiva Biotherapeutics' AlloNK, and multiple licensing agreements signaling significant innovation in the RA treatment landscape.

GlobeNewswire Inc.

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics announced that its management will participate in a panel and fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The clinical-stage biotech company is developing cell therapies for autoimmune diseases and cancers, with its lead program AlloNK currently in three ongoing clinical trials for B-cell driven autoimmune diseases.

GlobeNewswire Inc.

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer, bringing over 30 years of global leadership experience in pharmaceuticals, biotechnology, and medical devices. Huston received an inducement grant of 220,000 restricted stock units vesting over four years. The appointment comes as Artiva prepares to receive FDA feedback on its lead program AlloNK and share clinical efficacy data in rheumatoid arthritis in the first half of 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.